AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03725358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Health facilities assigned to this group will receive a two-week training intervention on modern contraceptive methods and counseling techniques - aimed at nurses conducting family planning services. This new curriculum was developed by a large group of experts convened by the Ministry of Health in February 2018. The cascade training that is developed by the national government (cascading down to regions, districts, and finally health facilities) is a 15-day training module that targets family planning nurses, covering theory, practical knowledge (practicing administrations and removals), and counseling of clients.
Study NCT03725358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Health facilities assigned to this group will receive the same programming as the facilities in S1, but they will also be provided with tablets equipped with the job aid, which subsumes the basic data collection software used by the remaining facilities. They will also receive additional training on the use of the tablet-based job aid.~The app is a tablet-based decision-support tool, which is designed for use by the family planning nurse conducting counseling sessions and records the answers to a series of questions that elicit the client's life goals, fertility plans, needs, and preferences regarding contraceptive methods, as well as her medical eligibility (birth history, pregnancy check, breastfeeding status, blood pressure, medications, etc.).
Study NCT03725358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: The comparison group includes facilities that continue business as usual (no FP training or tablet-based job aid). Each facility in this group will receive a tablet equipped with basic data collection software and a one-day training to use the tablets.
Study NCT06456749 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Integrated Disease Management
Description: For COPD, they are encouraged to seek further cares and manage COPD on a regular basis. For smokers, they will be given a digital health intervention based on CBT. For participants with symptoms of depression or anxiety, another digital health intervention is provided. For abnormal BMI participants, a knowledge brochure will be provided and a medical worker from the township hospital will tell the harm of abnormal BMI. For hypertension and type 2 diabetes, we will actively include them into the National Essential Public Health program.
Study NCT05510037 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention was needed
Study NCT05124470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive remediation by musical training sessions
Description: The musical learning method Diapason \& Metronome is unprecedented. It was specially created by Florent Cholat. It aims an apprenticeship of a musical practice adapted to subjects with schizophrenia. The method does not require the handling of a musical instrument; it is based on the voice and the body. It is built on the three essential dimensions of music, which are rhythm, single sound and harmony. Rhythm concerns the division and management of time. The single sound allows work on the representation of a sound object as a singularity. Harmony allows you to work on the positioning of a sound in the globality of the chord to which it belongs and in the collective polyphony exercises.
Study NCT05751213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: knack technique.
Description: It consists of 11 patients who will receive pelvic floor muscle exercise and knack technique at outpatient clinic and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine sustained for 6s with a resting interval twice as long between contractions, followed by 3 fast contractions. 3 times per day. 3 days per week at home for 3 months. 3 exercises in supine position. 8 repetitions of each exercise 3times per day , 3 days per week. .~Orientation to perform the knack during activities of daily life. The knack consists of voluntary pelvic floor muscles contraction before and during activities that increase abdominal pressure.~The exercise will be performed in the supine (first month), sitting (second month), and standing (third month) positions twice a month for 3 months at outpatient clinic. (6 outpatient sessions)
Study NCT05751213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor muscle exercises
Description: It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
Study NCT05751213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle exercises
Description: It consists of 11 patients who will receive pelvic floor muscle exercises at the outpatient and at home. 8 maximum voluntary contractions of pelvic floor muscles in supine position sustained for 6s with a resting interval twice as long between contractions followed by 3 fast contractions. 3 times per day , 3 days per week at home for 3 months. Two sessions per month at outpatient clinic for 3 months
Study NCT04998669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Description: Induction Phase (Cycles 1 through 4):~* 150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.~* 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.~Maintenance Phase 2 (Cycle 6 \& 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle.
Study NCT04998669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.~Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.~Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 1 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.
Study NCT06725615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Umami exposure
Description: This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile, which is about 20-25 mg/kg body weight.
Study NCT06725615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Umami exposure
Description: This group will receive the basic diet with added MSG, representing Dutch intake levels of around the 90th percentile, which is about 50-55 mg/kg body weight.
Study NCT04722640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKYRIZI
Description: SKYRIZI
Study NCT04734340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EIT-guided PEEP setting
Description: Ventilator parameter setting by EIT
Study NCT04734340 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ARDS-net PEEP setting
Description: Ventilator parameter setting according to ARDS-net table
Study NCT04889378 — intervention group
Intervention type: OTHER
Intervention: prehabilitation
Description: very low calories diet (800-1000kcal/day) with moderate intensive aerobic exercise (1 hour per section; 3 sections per day)
Study NCT06370884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMT
Description: a feeding tube placed at the time of surgery and receive IMT solution on postoperative day 2-3 (at least 48 hours following IV antibiotics) with the subsequent removal of the feeding tube.
Study NCT06565845 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: patients underwent complete excision of the inflammatory breast tissue and some surrounding normal tissue under combined intravenous with inhalation anesthesia. Damaged skin was also removed.
Study NCT06565845 — intervention group
Intervention type: DRUG
Intervention: triple anti-tuberculosis drug
Description: Patients took oral rifampin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day).
Study NCT05188274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: T92
Description: T92 granules (5g/sachet) will be taken BID for 8 weeks, the dosage will be calculated by individual's body weight.
Study NCT05188274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo matched to T92 granules will be taken BID for 8 weeks.
Study NCT06725615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Umami exposure
Description: This group will receive the basic diet without added MSG.
Study NCT06725615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one-week run-in period
Description: During the one-week run-in period, all participants will receive the RegularU diet, which is the basic diet with added MSG, representing Dutch intake levels of around the 50th percentile (about 20-25 mg MSG intake daily per kg body weight).
Study NCT04822467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ53 Wipe
Description: SQ53-based wipe to be used by the participant daily or upon dressing change
Study NCT04822467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol Wipe
Description: Ethanol-based wipe to be used by the participant daily or upon dressing change
Study NCT05639257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine tablets increasing dosis to maximal 300 mg daily
Study NCT05639257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Namuscla
Description: Namuscla tablets increasing dosis to maximal 501 mg daily
Study NCT04937140 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients
Description: assessment of 14-3-3 η (eta) protein antibodies in the serum of rheumatoid arthritis patients and Carotid Doppler ultrasound (for measurement of carotid intima media thickness and detection of plaques)
Study NCT06005662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
Study NCT06005662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: The proposed study is a double-blind, controlled investigation of the effect of 1 high-dose psilocybin (30 mg) session compared to a very low dose session (1 mg) following standard-of-care buprenorphine induction on drug abstinence, quality of life, craving, tobacco use, and treatment retention in healthy participants with an active OUD diagnosis
Study NCT04878029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT04878029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV
Study NCT04878029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04878029 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06498388 — intervention group
Intervention type: OTHER
Intervention: Stiffness measurement by visco-elastography
Description: Participant will be asked to put on the study's bra with the help of a female member of the team if necessary and to complete the examination process.
Study NCT06332924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational discussion group
Description: There will be 3 interviews with the motivational interview group, one week apart.
Study NCT05317923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation
Description: Anesthesia management in patients with subglottic tracheal stenosis with flow-controlled ventilation using an intubation tube with an inner diameter of less than 3 mm
Study NCT06303024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized combined physical and cognitive intervention
Description: The exercise intervention will be aerobic and performed on a stationary bicycle and will comply with the basic principle of progressive overload. An incremental exercise test until exhaustion on a bicycle ergometer will be applied to determine directly measured VO2-max in order to customize and personalize the training on each patient. The progressive aerobic exercise (PAE) will last 12 weeks with two sessions per week. Continuous training will be alternated with interval training during the program. The intervention included two weekly training sessions. One session will involve continuous exercise initially commencing at 10 min and progressing towards 30 min/session. Ultimately, a computer based cognitive rehabilitation program will be carried out twice a week for 12 weeks, using the Rehacom software. Participants will begin at level 1 on each RehaCom module and advance through the program as dictated by their performance. Each session will be programmed to last 60 minutes.
Study NCT06437522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06437522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT05963022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT05963022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT04882085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavicefta, Ceftazidime-Avibactam
Description: CAZ-AVI 2.5 g (2 g ceftazidime + 0.5 g avibactam) administered IV as a 2 hour infusion every 8 hours. Dose adjustments are available for participants with CrCL ≤50 mL/min.
Study NCT06666387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-MR examination
Description: PET-MR examination
Study NCT04882085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Treatment
Description: main treatment expected to be used as either monotherapy or in combination are colistin, tigecycline, fosfomycin, amikacin, and meropenem
Study NCT04905589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BetaQuik™
Description: MCT (Medium chain triglycerides)
Study NCT04905589 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WheyBasics
Description: Whey Protein Isolate
Study NCT04905589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Iso-voluminous water
Description: Iso-voluminous Water as comparitor to Betaquik or WheyBasics
Study NCT04905589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iso-voluminous water
Description: Iso-voluminous Water as comparitor to Betaquik or WheyBasics
Study NCT05285527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiSight 1 Day
Description: Subjects will wear MiSight 1 day lenses for three years.
Study NCT04688034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-724
Description: Twice a week for 4 hours continuous intravenous administration of OP-724.
Study NCT05480904 — intervention group
Intervention type: OTHER
Intervention: Neurocognitive (Thinking) Testing
Description: Intelligence: WASI-II 20 min; Sustained Attention:~Conners Continuous Performance Test 3rd ED. 15 min; Memory: California Verbal Learning Test 2nd Ed. 20 min; Visual Selective Reminding 7 min; Processing Speed:Coding/Digit Symbol 3 min; Grooved Pegboard 5 min; Executive Function: Trail Making Test 5 min; Verbal Fluency Test 3 min; Digit Span 5 min; Visuospatial: Rey Complex Figure 10 min; Functional Behavior: CCSS Neurocognitive Questionnaire 5 min.
Study NCT05480904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CNS Vital Signs (Thinking) Testing
Description: Attention: Continuous Performance Task 5 mins Processing Speed: Symbol Digit Test 4 mins Executive Function: Shifting Attention 3 min and Stroop Test 5 mins
Study NCT05480904 — intervention group
Intervention type: OTHER
Intervention: Health Questionnaires, Sleep Surveys & Sleep Diary
Description: The participant will be asked to complete the sleep surveys and sleep diary, FACIT fatigue, and CSALTS Pain Survey These questionnaires will take about 29 minutes to complete. The sleep diary is completed at the time the participant wears the sleep device.
Study NCT05480904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography/EKG
Description: All echocardiograms will be performed using a General Electric VIVID-7. The LV volume, mass and EF will be calculated using the recommendations of the American Society of Echocardiography
Study NCT05480904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pulmonary Function
Description: PFTs will include spirometry, lung volume measurements by body plethysmography and single breath carbon monoxide-diffusion capacity (DLCO).
Study NCT05480904 — intervention group
Intervention type: DEVICE
Intervention: Remote Polysomnography
Description: The Sleep Profiler PSG2/WatchPat device will be used to assess nighttime sleep disorders.
Study NCT05480904 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Physical Function
Description: This is a test of how your heart and lungs respond to exercise.
Study NCT05400590 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral venous blood sample
Description: 2.5% of body weight
Study NCT05400590 — intervention group
Intervention type: PROCEDURE
Intervention: Conjunctival impression
Description: Collection of the most superficial conjunctival epithelial cells (desquamating) in a non- or minimally invasive, quick and almost painless way, for a biological analysis of ocular surface diseases. Application of a filter paper on the bulbar conjunctiva, under local anesthesia.
Study NCT05362669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS invitation
Description: Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.
Study NCT05362669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone call invitation
Description: Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.
Study NCT04283513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virazole
Description: Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
Study NCT06128577 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3-month intensive intervention
Description: Intensive nutritional interventions were as follows: i）Estimation of ideal body weight according to height, calculation of calories by giving 30-40kcal/kg/day according to BMI stratification, and calculation of daily protein requirement at 1.5g/kg/day, which was finally converted into daily dietary recommendations according to the results of the calculations. ii）Distribution of additional protein supplementation by whey protein, each sachet containing 15g of whey protein.~The resistance training program included 5 min of warm-up, 20 min of muscle strength training, and 5 min of slow walking and was performed three times a week. Resistance training involved a dumbbell and sandbags as weights for the major muscles of the upper and lower limbs. In the study, aerobic training is brisk walking or jogging for 30 minutes/day, five times a week.
Study NCT04712370 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional caudal block
Description: Patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space) by the conventional method (blind technique without ultrasound).
Study NCT04712370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided caudal block
Description: Using ultrasound, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected in the caudal epidural space).
Study NCT04712370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane Block
Description: Under ultrasound guidance, patients of this group will receive (0.5ml/kg) (plain bupivacaine 0.25% injected beneath the erector spinae muscle sheath) at the level of the transverse process of the second lumbar vertebrae(L2).
Study NCT04924595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised exercise
Description: Personalised exercise intervention including aerobic and resistance training
Study NCT05038150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN1
Description: The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.